Marco Manca

Dr. Marco Manca

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Atherosclerosis
Verified
Journal Article
Closed access
Lauran StögerLauran Stöger
Lauran Stöger
MGMarion J.J. Gijbels
Marion J.J. Gijbels
SVSaskia van der Velden
Saskia van der Velden
Marco MancaMarco Manca
Marco Manca
CLChris M. van der Loos
Chris M. van der Loos
MWMenno de Winther
Menno de Winther

3 April 2012 in Circulation
Verified
Journal Article
Closed access
YDYvonne Döring
Yvonne Döring
HMHelga D. Manthey
Helga D. Manthey
MDMaik Drechsler
Maik Drechsler
DLDirk Lievens
Dirk Lievens
RMRemco T.A. Megens
Remco T.A. Megens
AZAlma Zernecke
Alma Zernecke
Background—: Inflammation has been closely linked to auto-immunogenic processes in atherosclerosis. Plasmacytoid dendritic cells (pDCs) are specialized to produce type-I interferons in response to pathogenic single-stranded nucleic acids, but can also sense self-DNA released from dying cells or in neutrophil extracellular traps complexed to the antimicrobial peptide Cramp/LL37 in autoimmune disease. However, the exact role of pDCs in atherosclerosis remains elusive. Methods and Results—: Here we demonstrate that pDCs can be detected in murine and human atherosclerotic lesions. Exposure to oxidatively modified low-density lipoprotein enhanced the capacity of pDCs to phagocytose and prime antigen-specific T cell responses. Plasmacytoid DCs can be stimulated to produce interferon-α by Cramp/DNA complexes, and we further identified increased expression of Cramp and formation of neutrophil extracellular traps in atherosclerotic arteries. Whereas Cramp/DNA complexes aggravated atherosclerotic lesion formation in apolipoprotein E–deficient mice, pDC depletion and Cramp-deficiency in bone marrow reduced atherosclerosis and anti–double-stranded DNA antibody titers. Moreover, the specific activation of pDCs and interferon-α treatment promoted plaque growth, associated with enhanced anti–double-stranded–DNA antibody titers. Accordingly, anti–double-stranded DNA antibodies were elevated in patients with symptomatic versus asymptomatic carotid artery stenosis. Conclusions—: Self-DNA (eg, released from dying cells or in neutrophil extracellular traps) and an increased expression of the antimicrobial peptide Cramp/LL37 in atherosclerotic lesions may thus stimulate a pDC-driven pathway of autoimmune activation and the generation of anti–double-stranded-DNA antibodies, critically aggravating atherosclerosis lesion formation. These key factors may thus represent novel therapeutic targets.

9 December 2011 in Circulation Research
Verified
Journal Article
Closed access
PDF file
IDIsabelle T.M.N. Daissormont
Isabelle T.M.N. Daissormont
ACAnette Christ
Anette Christ
LTLieve Temmerman
Lieve Temmerman
SMStefan Sampedro Millares
Stefan Sampedro Millares
TSTom T.P. Seijkens
Tom T.P. Seijkens
EBErik A.L. Biessen
Erik A.L. Biessen
Rationale:: Unlike conventional dendritic cells, plasmacytoid DCs (PDC) are poor in antigen presentation and critical for type I interferon response. Though proposed to be present in human atherosclerotic lesions, their role in atherosclerosis remains elusive. Objective:: To investigate the role of PDC in atherosclerosis. Methods and Results:: We show that PDC are scarcely present in human atherosclerotic lesions and almost absent in mouse plaques. Surprisingly, PDC depletion by 120G8 mAb administration was seen to promote plaque T-cell accumulation and exacerbate lesion development and progression in LDLr −/− mice. PDC depletion was accompanied by increased CD4 + T-cell proliferation, interferon-γ expression by splenic T cells, and plasma interferon-γ levels. Lymphoid tissue PDC from atherosclerotic mice showed increased indoleamine 2,3-dioxygenase (IDO) expression and IDO blockage abrogated the PDC suppressive effect on T-cell proliferation. Conclusions:: Our data reveal a protective role for PDC in atherosclerosis, possibly by dampening T-cell proliferation and activity in peripheral lymphoid tissue, rendering PDC an interesting target for future therapeutic interventions.

17 February 2016 in Clinical Science
Verified
Journal Article
Closed access
PDF file
RARaffaele Altara
Raffaele Altara
Marco MancaMarco Manca
Marco Manca
RBRita Brandão
Rita Brandão
AZAsad Zeidan
Asad Zeidan
GBGeorge W. Booz
George W. Booz
FZFouad A. Zouein
Fouad A. Zouein
The CXC chemokines, CXCL4, -9, -10, -11, CXCL4L1, and the CC chemokine CCL21, activate CXC chemokine receptor 3 (CXCR3), a cell-surface G protein-coupled receptor expressed mainly by Th1 cells, cytotoxic T (Tc) cells and NK cells that have a key role in immunity and inflammation. However, CXCR3 is also expressed by vascular smooth muscle and endothelial cells, and appears to be important in controlling physiological vascular function. In the last decade, evidence from pre-clinical and clinical studies has revealed the participation of CXCR3 and its ligands in multiple cardiovascular diseases (CVDs) of different aetiologies including atherosclerosis, hypertension, cardiac hypertrophy and heart failure, as well as in heart transplant rejection and transplant coronary artery disease (CAD). CXCR3 ligands have also proven to be valid biomarkers for the development of heart failure and left ventricular dysfunction, suggesting an underlining pathophysiological relation between levels of these chemokines and the development of adverse cardiac remodelling. The observation that several of the above-mentioned chemokines exert biological actions independent of CXCR3 provides both opportunities and challenges for developing effective drug strategies. In this review, we provide evidence to support our contention that CXCR3 and its ligands actively participate in the development and progression of CVDs, and may additionally have utility as diagnostic and prognostic biomarkers.

27 June 2021 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
HJHan Jin
Han Jin
PGPieter Goossens
Pieter Goossens
PJPeter Juhasz
Peter Juhasz
WEWouter Eijgelaar
Wouter Eijgelaar
Marco MancaMarco Manca
Marco Manca
EBErik A.L. Biessen
Erik A.L. Biessen
Background: While single‐omics analyses on human atherosclerotic plaque have been very useful to map stage‐ or disease‐related differences in expression, they only partly capture the array of changes in this tissue and suffer from scale‐intrinsic limitations. In order to better identify processes associated with intraplaque hemorrhage and plaque instability, we therefore combined multiple omics into an integrated model.Methods: In this study, we compared protein and gene makeup of low‐ versus high‐risk atherosclerotic lesion segments from carotid endarterectomy patients, as judged from the absence or presence of intraplaque hemorrhage, respectively. Transcriptomic, proteomic, and peptidomic data of this plaque cohort were aggregated and analyzed by DIABLO, an integrative multivariate classification and feature selection method.Results: We identified a protein‐gene associated multiomics model able to segregate stable, nonhemorrhaged from vulnerable, hemorrhaged lesions at high predictive performance (AUC >0.95). The dominant component of this model correlated with αSMA−PDGFRα+fibroblast‐like cell content (p = 2.4E‐05) and Arg1+macrophage content (p = 2.2E‐04) and was driven by serum response factor (SRF), possibly in a megakaryoblastic leukemia‐1/2 (MKL1/2) dependent manner. Gene set overrepresentation analysis on the selected key features of this model pointed to a clear cardiovascular disease signature, with overrepresentation of extracellular matrix synthesis and organization, focal adhesion, and cholesterol metabolism terms, suggestive of the model's relevance for the plaque vulnerability. Finally, we were able to corroborate the predictive power of the selected features in several independent mRNA and proteomic plaque cohorts.Conclusions: In conclusion, our integrative omics study has identified an intraplaque hemorrhage‐associated cardiovascular signature that provides excellent stratification of low‐ from high‐risk carotid artery plaques in several independent cohorts. Further study revealed suppression of an SRF‐regulated disease network, controlling lesion stability, in vulnerable plaque, which can serve as a scaffold for the design of targeted intervention in plaque destabilization.

6 June 2016 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
RARaffaele Altara
Raffaele Altara
Marco MancaMarco Manca
Marco Manca
MHMarleen H. Hessel
Marleen H. Hessel
YGYumei Gu
Yumei Gu
LVLaura C. van Vark
Laura C. van Vark
WBW. Matthijs Blankesteijn
W. Matthijs Blankesteijn